louisiana glp-1 gastric intestinal obstruction lawyer Ozempic Lawsuit [2026 Update] glp-1 bowel obstruction lawyer in

FDA-APPROVED INDICATIONS Type 2 diabetes As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus Limitations of use: has not been studied in patients with a history of pancreatitis TYPE 2 DIABETES RCT SURPASS-2 trial - Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes, NEJM (2021) [PubMed abstract] The SURPASS-2 trial enrolled 1879 adults with type 2 diabetes who were inadequately controlled with metformin at a dose of at least 1500 mg per day Main inclusion criteria Age 18 years T2DM uncontrolled with metformin at 1500 mg/day A1C of 7 - 10.5% BMI 25 and stable for 3 months Main exclusion criteria Type 1 diabetes GFR 50 ng/L

Some experts note that better mental health often follows improvements in physical health, making it difficult to disentangle whether GLP-1 drugs have unique neurobiological effects or whether benefits arise from downstream consequences like weight loss and stabilized blood sugar

More significantly, RA patients already on DMARDs (disease-modifying antirheumatic drugs) who added a GLP-1 agonist had fewer disease flares than those on DMARDs alone

This suggests that not only did the GLP-1 improve their metabolic profile, but it also improved their methylation

consumers were actively seeking to increase their protein intake, according to the International Food Information Council 2024 Food & Health Survey

3.4 Early PsA and future research directions Despite the promising metabolic and immunomodulatory effects observed in PsO, the role of GLP-1RAs in PsA, particularly in its early stages, remains largely unexplored